Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
States and the federal government are under growing pressure to legalize the use of cannabis products for medical purposes in the United States. Sixteen states have legalized (or decriminalized possession of) products high in cannabidiol (CBD) and with restricted ∆(9) -tetrahydrocannabinol (∆(9) -THC) content. In most of these states, the intent is for use in refractory epileptic seizures in children, but in a few states, the indications are broader. This review provides an overview of the pharmacology and toxicology of CBD; summarizes some of the regulatory, safety, and cultural issues relevant to the further exploitation of its antiepileptic or other pharmacologic activities; and assesses the current status and prospects for clinical development of CBD and CBD-rich preparations for medical use in the United States. Unlike Δ(9) -THC, CBD elicits its pharmacologic effects without exerting any significant intrinsic activity on the cannabinoid receptors, whose activation results in the psychotropic effects characteristic of Δ(9) -THC, and CBD possesses several pharmacologic activities that give it a high potential for therapeutic use. CBD exhibits neuroprotective, antiepileptic, anxiolytic, antipsychotic, and antiinflammatory properties. In combination with Δ(9) -THC, CBD has received regulatory approvals in several European countries and is currently under study in trials registered by the U.S. Food and Drug Administration in the United States. A number of states have passed legislation to allow for the use of CBD-rich, limited Δ(9) -THC-content preparations of cannabis for certain pathologic conditions. CBD is currently being studied in several clinical trials and is at different stages of clinical development for various medical indications. Judging from clinical findings reported so far, CBD and CBD-enriched preparations have great potential utility, but uncertainties regarding sourcing, long-term safety, abuse potential, and regulatory dilemmas remain.
The National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS.
Pius S
PS
Fasinu
The National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS.
Sarah
S
Phillips
The National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS.|Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS.
Mahmoud A
MA
ElSohly
The National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS.|Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, MS.
Larry A
LA
Walker
D002185:Cannabidiol / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013759:Dronabinol / Q000627:therapeutic use; D063388:Endocannabinoids / Q000502:physiology; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D065768:Lennox Gastaut Syndrome / Q000188:drug therapy; D043882:Receptors, Cannabinoid / Q000502:physiology
D063388:Endocannabinoids; D043882:Receptors, Cannabinoid; D002185:Cannabidiol; D013759:Dronabinol
cannabidiol; cannabis; drug development; medical marijuana; ∆9-tetrahydrocannabinol